Park Sehoon, Baek Chung Hee, Park Su-Kil, Kang Hee Gyung, Hyun Hye Sun, Park Eujin, Han Seung Hyeok, Ryu Dong-Ryeol, Kim Dong Ki, Oh Kook-Hwan, Joo Kwon Wook, Kim Yon Su, Moon Kyung Chul, Chin Ho Jun, Lee Hajeong
Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kidney Blood Press Res. 2019;44(1):22-32. doi: 10.1159/000497808. Epub 2019 Feb 22.
BACKGROUND/AIMS: Additional validation study was warranted to confirm the clinical significance of C score, which was recently added to the Oxford classification for immunoglobulin A nephropathy (IgAN).
We performed a multicenter retrospective cohort study in four hospitals in Korea. Patients who had biopsied glomeruli less than eight or inadequate follow-up information were excluded. Clinicopathologic parameters, including the degree of cellular or fibrocellular crescents, were collected and included in multivariable models for Cox regression analysis. The main outcome was a composite renal outcome, defined as a merge of progression to end-stage renal disease (ESRD) and halving of estimated glomerular filtration rate (eGFR) from baseline.
Among included 3,380 biopsy-confirmed IgAN patients, there were 664 (19.6%) patients with C1 and 60 (1.8%) patients with C2 scores in the study population. Although C0 and C1 patients shared similar baseline characteristics, C2 patients frequently had more clinicopathologic risk factors for poor prognosis of IgAN. Both C1 [adjusted HR 1.33 (1.11-1.58), P=0.002] and C2 [adjusted HR 2.24 (1.46-3.43), P< 0.001] scores were associated with an increased risk of the composite outcome. C2 was a strong predictive parameter associated with both progression to ESRD and halving of eGFR, whereas C1 was mainly associated with the increased risk of halving of eGFR. Notably, the proportion of crescent showed a linear association with the risk of adverse renal outcome.
The C score in the Oxford classification is a valid predictive parameter for IgAN prognosis. Additional clinical attention is necessary for IgAN patients with identified cellular or fibrocellular crescents.
背景/目的:鉴于C评分最近被纳入免疫球蛋白A肾病(IgA肾病)的牛津分类,有必要进行额外的验证研究以确认其临床意义。
我们在韩国的四家医院进行了一项多中心回顾性队列研究。排除肾小球活检数量少于8个或随访信息不充分的患者。收集包括细胞性或纤维细胞性新月体程度在内的临床病理参数,并纳入多变量Cox回归分析模型。主要结局是复合肾脏结局,定义为进展至终末期肾病(ESRD)和估计肾小球滤过率(eGFR)从基线减半的合并情况。
在纳入的3380例经活检确诊的IgA肾病患者中,研究人群中有664例(19.6%)为C1评分,60例(1.8%)为C2评分。尽管C0和C1患者具有相似的基线特征,但C2患者IgA肾病预后不良的临床病理危险因素往往更多。C1[调整后风险比(HR)1.33(1.11 - 1.58),P = 0.002]和C2[调整后HR 2.24(1.46 - 3.43),P < 0.001]评分均与复合结局风险增加相关。C2是与进展至ESRD和eGFR减半均相关的强预测参数,而C1主要与eGFR减半风险增加相关。值得注意的是,新月体比例与不良肾脏结局风险呈线性相关。
牛津分类中的C评分是IgA肾病预后的有效预测参数。对于已确定存在细胞性或纤维细胞性新月体的IgA肾病患者,需要给予额外的临床关注。